Viking Global Investors’s Vertex Pharmaceuticals VRTX Stock Holding History

Viking Global Investors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,421,673	Closed	-$179M	–	79
2015 Q4	$179M	Buy	1,421,673 +77,209	+6%	+$9.32M	0.67%	35
2015 Q3	$140M	Sell	1,344,464 -460,722	-26%	-$59.2M	0.54%	43
2015 Q2	$223M	Buy	1,805,186 +35,036	+2%	+$4.41M	0.84%	32
2015 Q1	$209M	Buy	1,770,150 +1,005,950	+132%	+$121M	0.81%	35
2014 Q4	$90.8M	Buy	+764,200	New	+$86.1M	0.42%	48

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Viking Global Investors's VRTX Position: Q1 2016 in Review

Viking Global Investors sold out of Vertex Pharmaceuticals (VRTX) in Q1 2016, closing a stake of 1,421,673 shares — an estimated $179M sold.

Viking Global Investors first reported a position in VRTX in Q4 2014 and held it in 5 quarters. The position peaked at $223M in Q2 2015. 502 funds tracked by Wall St. Rank hold VRTX as of Q1 2016.

Viking Global Investors reported no remaining Vertex Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Viking Global Investors sold 1,421,673 Vertex Pharmaceuticals shares in Q1 2016, an estimated $179M.
Viking Global Investors first reported a position in Vertex Pharmaceuticals in Q4 2014 and held it in 5 quarters.
Viking Global Investors's Vertex Pharmaceuticals position peaked at $223M in Q2 2015.
502 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2016.

Based on Viking Global Investors's 13F filing for Q1 2016, filed 16 May 2016.